Alumis (ALMS) Net Income towards Common Stockholders Growth (3y) (2026)
Powered by 
Analysis
Alumis (ALMS) Net Income towards Common Stockholders Growth (3y) (2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -38.56% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 62.15% |
| 10 | Alumis | 1.42 Bn | 913.89 Mn | - | -57.04% |